US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Key evidence in the 'burking' murder trial was 'hidden' from defence lawyers
Key evidence which undermined the police case against a man convicted of the so-called 'burking' mur2024-05-21Congressman praises heckling of war protesters, including 1 who made monkey gestures at Black woman
JACKSON, Miss. (AP) — Israel-Hamas war demonstrations at the University of Mississippi turned ugly t2024-05-21- SINGAPORE (AP) — Sebastian Munoz of Colombia shot a 6-under 65 on Friday to lead after the first rou2024-05-21
Twins stretch win streak to 11 with 5
MINNEAPOLIS (AP) — Chris Paddack pitched six scoreless innings to carry the Minnesota Twins to their2024-05-21Four people killed in a house explosion in southwestern Missouri
GOODHOPE, Mo. (AP) — Four people in rural Missouri died when an explosion that could be heard 10 mil2024-05-21- RIYADH, April 30 (Xinhua) -- Saudi Arabia announced the plan to launch a Riyadh-based multi-asset in2024-05-21
atest comment